Clinical Trials Logo

Clinical Trial Summary

The primary objectives of the study are: - To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time. - To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities The secondary objectives of the study are: - To characterize real-world utilization of DUPIXENT® for patients with CRSwNP - To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP - To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04959448
Study type Observational
Source Regeneron Pharmaceuticals
Contact
Status Active, not recruiting
Phase
Start date August 12, 2021
Completion date July 25, 2027